ResearcherWestlake UniversityActive in the last 2 years
Mengyao Tian
Matched on OpenAlex author ID A5045203904. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2022: 2 papers · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 4
- Securinine suppresses pancreatic cancer progression by activating the p38 MAPK pathway to upregulate CHOP and induce endoplasmic reticulum stress. Co-author DOI 10.1016/j.bbadis.2026.168229↗
- Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and trigger endoplasmic reticulum stress. Co-author DOI 10.1016/j.intimp.2024.113497↗
- Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway. First author DOI 10.1155/2022/8675096↗
- Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in vitro. Co-author DOI 10.7150/jca.65875↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dongchao Xu · 3 shared papers, 2022–2024 · strength 0.59
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in… DOI 10.7150/jca.65875↗
- Paper Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signali… DOI 10.1155/2022/8675096↗
- Hongzhang Shen · 3 shared papers, 2022–2024 · strength 0.59
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in… DOI 10.7150/jca.65875↗
- Paper Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signali… DOI 10.1155/2022/8675096↗
- Xiaofeng Zhang · 2 shared papers, 2022–2024 · strength 0.43
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Cucurbitacin I inhibits the proliferation of pancreatic cancer through the JAK2/STAT3 signalling pathway in vivo and in… DOI 10.7150/jca.65875↗
- Dongchao Xu · 1 shared paper, 2026 · strength 0.39
- Qiang Liu · 2 shared papers, 2022–2024 · strength 0.39
- Paper Isolinderalactone suppresses pancreatic ductal adenocarcinoma by activating p38 MAPK to promote DDIT3 expression and tr… DOI 10.1016/j.intimp.2024.113497↗
- Paper Linderalactone Suppresses Pancreatic Cancer Development In Vitro and In Vivo via Negatively Regulating PI3K/AKT Signali… DOI 10.1155/2022/8675096↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.